Immune Profiling for Cancer Immunotherapy Response
Dartmouth-Hitchcock Medical Center
1,500 participants
Oct 3, 2022
OBSERVATIONAL
Conditions
Summary
In patients clinically treated with FDA-approved immunotherapy the investigators will assess the predictive value of pre- and on-treatment 1) immune-methylation profiling across cancer types, and 2) immune-methylation profiling and cytokine profiling within cancer types.
Eligibility
Inclusion Criteria2
- Cancer patients receiving or will receive immunotherapy under FDA- approved indication (e.g. checkpoint inhibitor therapy with pembrolizumab, nivolumab, or ipilimumab, or cellular immunotherapy).
- Participants are eligible regardless of the type of prior therapy (i.e. prior immunotherapy treated participants can be included).
Exclusion Criteria3
- Pregnant women/fetuses/neonates
- Prisoners
- Decision-impaired individuals
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06116032